5,646 件 ・ 関連度順
概要と使いどころ
Use when defending the research design of an American Educational Research Journal (AERJ) manuscript — quantitative (multilevel, IRT, quasi-experimental, RCT), qualitative (case study, ethnography, interview), or mixed methods. AERJ judges each tradition on its own terms against the AERA reporting standards. Strengthens the design; it does not write code.
日本語の概要は準備中です。原文の説明を表示しています。
Use when targeting the Journal of Cleaner Production or deciding whether a cleaner-production/sustainability manuscript fits this venue. Encodes the journal's fit, the cleaner-production contribution and methodological-transparency bar, LCA/system-boundary expectations, house style, official-submission re-check, and desk-reject heuristics.
日本語の概要は準備中です。原文の説明を表示しています。
Use when building the conceptual/theoretical argument of an American Anthropologist (AA) manuscript into a four-field contribution — whether the work is ethnographic, archaeological, biological, or linguistic. AA rewards a portable concept and reflexive argument over a bare finding or thick description alone. Structures the argument; it does not run analyses or write fieldnotes.
日本語の概要は準備中です。原文の説明を表示しています。
Use when deciding whether a materials result clears Advanced Materials' advance-and-broad-impact gate, or whether it belongs in Advanced Functional Materials, Advanced Science, Small, or Advanced Materials Interfaces. Diagnoses venue fit; does not write or characterize the material.
日本語の概要は準備中です。原文の説明を表示しています。
Use when deciding what characterization and experimental detail an Advanced Materials manuscript must show to prove its structure–property claim, and what belongs in the Experimental Section and Supporting Information. Partitions and stress-tests methods; does not design figures or run analysis.
日本語の概要は準備中です。原文の説明を表示しています。
Use when choosing and justifying the research design for an Administrative Science Quarterly (ASQ) manuscript — qualitative (grounded-theory, ethnographic, historical) or quantitative — and setting the rigor bar. Designs the study; it does not run the analysis (see asq-data-analysis).
日本語の概要は準備中です。原文の説明を表示しています。
Use when designing the study for an Accounting, Organizations and Society (AOS) manuscript — qualitative field studies (access, case logic, interviews, observation), behavioral experiments, surveys, historical/archival inquiry, or theory-laden archival designs, each with the ethics and site-anonymity groundwork done early. Designs the inquiry; it does not run the coding or estimation (aos-data-analysis).
日本語の概要は準備中です。原文の説明を表示しています。
Use when running and reporting the statistical analysis for an Academy of Management Journal (AMJ) manuscript — measurement validity, common-method bias, the right estimator (HLM, SEM, panel, experiments), endogeneity, and robustness. Executes and reports the analysis; it does not design the study (amj-methods) or frame the contribution (amj-contribution-framing).
日本語の概要は準備中です。原文の説明を表示しています。
Use when deciding whether a project is a strong AAMAS fit, comparing AAMAS with AAAI, IJCAI, NeurIPS, ICML, EC, and the JAAMAS journal, identifying whether the agents are truly the research object, naming the interaction primitive (solution concept, mechanism, coordination, negotiation), and sharpening the multiagent framing before writing begins.
日本語の概要は準備中です。原文の説明を表示しています。
End-to-end news-triggered signal composite. Takes any piece of news — an article, LinkedIn post, tweet, announcement, event, trend, regulation, product launch, acquisition, layoff, expansion, or any other public event — and evaluates whether the companies or people mentioned are ICP fits. If yes, identifies the connection between the news and your product, finds the right people to contact, and drafts personalized outreach using the news as the hook. Tool-agnostic. Accepts both company-level and person-level news triggers. AUTO-TRIGGER: Load this composite whenever a user shares a URL (LinkedIn post, article, tweet, blog post) or mentions a company/person they "came across", "saw", or "found" from any external source and asks about relevance, fit, ICP match, or whether to reach out. The user does NOT need to explicitly say "outreach" — any signal evaluation request from an external source triggers this.
日本語の概要は準備中です。原文の説明を表示しています。
Organize DI registrations using IServiceCollection extension methods. Group related services into composable Add* methods for clean Program.cs and reusable configuration in tests.
日本語の概要は準備中です。原文の説明を表示しています。
Phases small variants, SVs, and methylation from Oxford Nanopore and PacBio long reads (read-backed/physical phasing) with WhatsHap, LongPhase, or HiPhase, and haplotags the BAM (HP/PS tags) for allele-resolved downstream analysis. Covers why phase blocks break at het-sparse gaps (read length x heterozygosity), why phasing the VCF is useless until the BAM is haplotagged, the GT-pipe/PS and read HP/PS tag spec, reporting block N50 with switch error, the diploid-assumption/CNV/haploid-region traps, trio phasing as the gold standard, and the boundary to statistical panel phasing. Use when phasing long-read variants, haplotagging reads for allele-specific methylation/expression or phased SVs, choosing WhatsHap vs LongPhase vs HiPhase, trio phasing, or assessing phasing quality.
日本語の概要は準備中です。原文の説明を表示しています。
Estimates tumor fraction (the genome-wide proportion of cfDNA molecules that are tumor-derived, the cfDNA analogue of bulk-tumor purity) from shallow whole-genome sequencing with ichorCNA, an HMM over 1 Mb bins that jointly EM-estimates tumor fraction, ploidy, and subclonal prevalence over a normal/ploidy grid. Encodes the load-bearing reframes: tumor fraction is the quantity that travels across assays and is NOT mutation VAF (clonal-het VAF approximately TF/2), CNA-based estimation has a hard ~3 percent limit-of-detection floor, and near-diploid or copy-neutral-LOH genomes return a falsely low value. Selects the estimator by data type (sWGS to ichorCNA, deep panel to max-VAF, methylation to deconvolution, sub-3 percent to fragmentomics or methylation). Use when quantifying tumor burden from a liquid biopsy, picking a tumor-fraction estimator for a given assay, or reconciling a TF estimate against a panel VAF.
日本語の概要は準備中です。原文の説明を表示しています。
Analyze spatial cell-cell interactions, neighborhoods, and niches in IMC/MIBI data with squidpy and imcRtools, covering neighborhood-enrichment permutation nulls, the abundance-vs-density confound, inhomogeneous Ripley's K, cellular-neighborhood discovery, graph-construction (contact vs proximity), and edge effects. Use when testing whether cell types co-locate, choosing a spatial null, building a neighbor graph, discovering tissue niches, or deciding whether a spatial pattern is real or a density/segmentation artifact.
日本語の概要は準備中です。原文の説明を表示しています。
Basecalls raw Oxford Nanopore signal (POD5/FAST5) into reads with Dorado, choosing the chemistry-matched model and accuracy tier (fast/hac/sup), requesting modified bases (5mCG_5hmCG, 6mA, m6A) at basecall time, and handling duplex, demultiplexing, trimming, and HERRO read correction. Covers why the model+version is an irreversible analysis decision, why methylation cannot be recovered later, and why downstream polish/variant models must match the basecaller. Use when converting POD5/FAST5 to reads, picking a Dorado model for R9/R10 or RNA004, enabling methylation calling, basecalling duplex, demultiplexing barcoded runs, or correcting reads for assembly.
日本語の概要は準備中です。原文の説明を表示しています。
Compare cell-type composition and spatial features across conditions in IMC/MIBI cohorts with the patient as the experimental unit, covering pseudoreplication, per-patient aggregation, mixed models, compositional (Dirichlet/scCODA) differential abundance, diffcyt, per-image-to-patient spatial differential testing (SpaceANOVA), batch covariates, and FDR. Use when testing whether a cell type or spatial niche differs between groups, avoiding cell-level pseudoreplication, choosing a differential-abundance method, or correctly powering an IMC cohort comparison.
日本語の概要は準備中です。原文の説明を表示しています。
Tests whether two genomic interval sets overlap (colocalize) more than expected by chance using a permutation test against a structured-genome null model. Covers bedtools fisher (analytic 2x2 screen), bedtools shuffle + jaccard permutation, GAT (isochore/GC-conditioned simulation with FDR), regioneR (flexible permutation, randomizeRegions vs circularRandomizeRegions, localZScore), LOLA (universe-relative Fisher against a region database), and GREAT/rGREAT (regulatory-domain binomial + hypergeometric for ontology-from-regions). Stresses the universe/background choice, matched background, blacklist exclusion, and multiple-testing control. Use when asking whether peaks/regions are enriched at enhancers/TFBS/features, scoring region-set colocalization or region-set enrichment, comparing CNV/SV concordance, or turning an overlap count into a defensible p-value.
日本語の概要は準備中です。原文の説明を表示しています。
Infer gene regulatory networks from bulk or general expression data with mutual-information (ARACNe) and tree-ensemble (GENIE3, GRNBoost2) methods, and infer transcription-factor protein activity from regulons with VIPER and msVIPER. Covers the activity-not-edges paradigm, the undirected-association caveat, the DREAM5 wisdom-of-crowds and method-complementarity result, AUPRC-over-AUROC evaluation, and gold-standard incompleteness. Use when inferring a regulatory network from a bulk expression matrix, finding master regulators, or scoring TF activity from a signature. For single-cell motif-pruned regulons see scenic-regulons; for co-expression modules see coexpression-networks.
日本語の概要は準備中です。原文の説明を表示しています。
Aligns and QCs methylated-RNA-immunoprecipitation (MeRIP / m6A-seq) IP and input libraries using STAR or HISAT2 splice-aware mapping, samtools sort/index, IP/input matched-pair tracking, antibody-lot metadata recording, replicate concordance via deepTools multiBamSummary + plotCorrelation, IP enrichment QC via plotFingerprint and per-transcript IP/input ratio distributions, library-complexity saturation curves via PreSeq, and the explicit do-NOT-deduplicate convention for standard non-UMI MeRIP. Use when preparing paired IP and input BAM files for exomePeak2 / MeTPeak / MACS3 peak calling, evaluating MeRIP replicate concordance and IP enrichment, deciding whether to deduplicate (standard MeRIP typically NOT), choosing genome-vs-transcriptome alignment for downstream peak vs m6Anet workflows, recording antibody clone and lot metadata for cross-batch reconciliation, detecting failed IPs via saturation curves and IP/input distribution shape, or generating IP-over-Input bigWig tracks for visualisation.
日本語の概要は準備中です。原文の説明を表示しています。
Designs genomics experiments so technical nuisance variation (batch, lane, plate, flow cell, operator, reagent lot, processing day) is balanced against the biological variable of interest and therefore estimable rather than confounded, using constrained sample-to-batch assignment (designit, OSAT), the confounder/mediator/collider distinction, and the principle that no post-hoc correction recovers a fully confounded design. Covers detecting hidden batches with surrogate variable analysis, a decision table for downstream correction (ComBat-seq, RUVSeq, SVA) whose execution is deferred to differential-expression/batch-correction, and reproducibility metadata. Use when assigning samples to sequencing batches/lanes/plates, avoiding batch-condition confounding, deciding whether a design is salvageable by correction, choosing a correction method, or estimating the number of hidden batches. For the experimental unit, randomization, and blocking concepts see experimental-design/randomization-blocking.
日本語の概要は準備中です。原文の説明を表示しています。
Calls m6A peaks from MeRIP-seq / m6A-seq paired IP-vs-input data using exomePeak2 (transcript-aware, GC-bias-corrected Poisson GLM), MeTPeak (HMM over sliding windows), MACS3/MACS2 with --nomodel --broad --keep-dup all (genome-wide broad alternative), and DRACH motif enrichment via HOMER or ggseqlogo as a sanity check (NOT a filter). Covers BED12 vs narrowPeak output, exonic vs intronic peak handling, multi-tool reconciliation (intersection vs union), the m6A-vs-m6Am ambiguity at 5'UTR peaks that antibody methods cannot resolve, and orthogonal validation (miCLIP/GLORI/m6A-SAC-seq/m6Anet). Use when calling peaks from paired IP/input genome BAMs, choosing exomePeak2 (transcript-aware default) vs MACS3 (broad genomic) vs MeTPeak (HMM-smoothed low-coverage), confirming DRACH enrichment as a sanity check on the peak set, reconciling differing peak sets across tools, validating MeRIP peaks against single-base methods, interpreting 5' peaks where m6Am contamination is possible, or recommending a consensus strategy.
日本語の概要は準備中です。原文の説明を表示しています。
Identifies differential m6A methylation between conditions from MeRIP-seq paired IP/input data using exomePeak2 (GC-bias-aware differential via its bam_ip/bam_input control + bam_treated_ip/bam_treated_input treatment arms), QNB beta-binomial, MeTDiff HMM, and RADAR, plus the paired-symmetric edgeR/DESeq2-on-peak-counts route when batch/lot covariates need fixed-effect handling that exomePeak2's API does not accept. Covers paired vs unpaired vs interaction designs, batch confounding and per-lot meta-analysis, the stoichiometry-vs-expression-vs-IP-efficiency confound, and effect-size filtering against under-powered N=2 designs. Use when comparing m6A across two or more conditions, choosing between exomePeak2/QNB/RADAR/MeTDiff for a design, handling batch confounding when exomePeak2's API is too rigid, distinguishing real hyper/hypo-methylation from expression shifts, applying effect-size thresholds, or planning orthogonal stoichiometry validation (GLORI/SAC-seq/m6Anet mod_ratio).
日本語の概要は準備中です。原文の説明を表示しています。
Calculates statistical power for high-dimensional genomics experiments (bulk RNA-seq, scRNA-seq, ATAC-seq, ChIP-seq, methylation, proteomics) under negative-binomial count models using RNASeqPower, PROPER, and simulation via powsimR, distinguishing per-gene from marginal (transcriptome-wide) power, the role of mean expression and dispersion, and the sequencing-depth-versus-replicate tradeoff. Covers simulation as the honest default for overdispersed counts, FDR-aware average power versus single-test power, observed/post-hoc power as an anti-pattern, and the winner's-curse / Type-S / Type-M consequences of underpowering. Use when planning replicate number for a sequencing experiment, deciding whether to add depth or samples, choosing closed-form versus simulation power, estimating power from pilot dispersions, or justifying replication in a grant. For clinical-trial power see clinical-biostatistics/power-and-sample-size; for the inverse sample-size question see experimental-design/sample-size.
日本語の概要は準備中です。原文の説明を表示しています。
Quality control for pooled CRISPR screens covering library representation, Gini index, log-skew, replicate Pearson and Spearman concordance, essentialome precision-recall AUC against CEGv2 (Hart 2017), Cas9 cut-toxicity diagnostics, copy-number amplicon detection (Aguirre 2016 / Munoz 2016), bottleneck propagation through plasmid pool, infection, selection, and endpoint stages, MOI verification, and DepMap-style screen-quality scoring. Use when assessing screen quality before hit calling, deciding whether to repeat or rescue a screen, diagnosing low-confidence hits, choosing between MAGeCK / BAGEL2 / Chronos based on quality grade, picking a normalization strategy from QC signatures, or evaluating whether an in-vivo screen retained adequate library complexity.
日本語の概要は準備中です。原文の説明を表示しています。